Extraesophageal Reflux Disease – Interdisciplinary Consensus
Authors:
J. Vydrová 6; Karol Zeleník 7
; P. Brandtl 1; K. Lukáš 2; J. Turzíková 3; J. Chlumsk 4; V. Sedlák 5; J. Vojtíšková 8; B. Seifert 8
Authors‘ workplace:
Gastroenterologická ambulance, Praha
1; IV. interní klinika 1. LF UK a VFN, Praha
2; Dětská pneumologická ambulance FN Bulovka, Praha
3; Pneumologická klinika 1. LF UK a FTNsP, Praha
4; Plicní klinika LF UK a FN, Hradec Králové
5; Hlasové a sluchové centrum Medical Healthcom s. r. o., Praha
6; Otorinolaryngologická klinika FN Ostrava
7; Ústav všeobecného lékařství 1. LF UK, Praha
8
Published in:
Otorinolaryngol Foniatr, 60, 2011, No. 2, pp. 63-70.
Category:
Original Article
Overview
In view of the increasing incidence and prevalence of the esophageal reflux disease (ERD) there is also an increasing incidence and prevalence of the extraextraesophageal reflux disease (EERD). There is a pressing need for determination of the approach to the patients at the interdisciplinary level. The material is based on the already elaborated and updated standards for ERD (1). Extraesophageal reflux (EER) is a condition when there is the penetration of the duodenal/gastric content above the level of upper esophageal sphincter (UES). Extraesophageal reflux disease (EERD) is a condition when the reflux causes complaints and/or complications in the larynx, pharynx, respiratory tract and oral cavity. In case of the heart rate disorders and in some cases of bronchial asthma and cough the reflux content does not reach above the level of upper esophageal sphincter. The case is the irritation of a nervus vagus branch and there are therefore extraesophageal manifestations of ERD. The precise prevalence of EERD is not known; the group of patients is not homogeneous and the severity of symptoms varies. The signs and symptoms of EERD have been encountered in 4 % - 10 % of U.S. patients attending the ORL out-patient department (2). Etiopathogenesis of EERD does not significantly differ from ERD. The degree of damage depends of prevailing aggressive factors over defensive ones. The insufficiency of upper esophageal sphincter is considered to be the most important cause. The chemical composition of the reflux content is the important pathogenetic factor as well as the duration of exposure on the mucosa of individual organs. The sleep reflux may play a role as well (3, 4).
In more distant regions (middle ear, paranasal cavities, lungs), the role reflux aerosols is presumed. Typical symptoms of esophageal reflux disease include heartburn and regurgitation, but these are encountered only in a part of patients with extraesophageal reflux disease (in 6 to 43% of patients with ORL complaints, in 40 to 60% of patients with asthma and in 25 to 57% of patients with cough. The establishment of diagnosis of extraesophageal reflux disease is not simple and there is no specific diagnostic method available. The therapy must be complex in nature and consists of regimen and diet measures. The medication treatment applies antacids, prokinetics, proton pump inhibitors and in some cases bile acid adsorbents. Laparoscopic fundoplication is indicated in specific cases only after the conservative therapy has failed.
Key words:
esophageal reflux disease, medicament treatment, laparoscopic fundoplication.
Sources
1. AGA medical position statement on the management of gastroesophageal reflux disease. Gastroenterology, roč. 135, 2008, č. 4, s. 1383-1391 (27).
2. Altman, K. W, Irwin, R. S., Cough: An interdisciplinary problem. Otolaryngol. Clin. N Amer., 43, 2010, s. 1-13 (19).
3. Ayazi, S., Lipham, J. C., Hagen, J. A. et al.: A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. J. Gastrointest Surg., 2009, 13, s. 1422-1429 (10).
4. Belafsky, C. P., Postma, G. N., Amin, R. M., Koufman, J. M.: Symptoms and findings of laryngopharyngeal reflux. Ear, Nose & Throat Journal, 81, 2002, 9, s. 10-13, 18 (25).
5. Belafsky, C. P., Postma, G. N., Koufman, J. M.: The validity and reliability of the reflux finding score. Laryngoscope, 111, 2001, s. 1313-1317.
6. El-Serag, H. B., Hepworth, E. J., Lee, P. et al.: Gastroesophageal reflux disease is a risk factor for laryngeal and pharyngeal cancer. Am. J. Gastroenterol., 96, 2001, s. 2013-2018.
7. Galmiche, J. P.: Non-erosive reflux disease and atypical gstro-oesophageal reflux disease mnifestations: Treatment rsults. Drugs, 66, 2006, Suppl. 1, s. 7-13.
8. Gill, G. A., Artur, C., Hampson, F., Dettmar, P. W., Moorghan, M., Pignatelli, M.: Characterisation of acid and pepsin damaged laryngeal and oesophageal mucosa. Gastroenterology, 122, 2002, (Suppl. 4), s. 415.
9. Johnston, N., Dettmar, P. W., Bishwokarma, B. et al.: Activity/stability of human pepsin: implications for reflux attributed laryngeal disease. Laryngoskope, 117, 2007, s. 1036-1039.
10. Johnston, N., Dettmar, P. W., Lively, M. O. et al.: Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngopharyngeal reflux disease. The Annals of Otology, Rhinology & Laryngology, 115, 2006, s. 47-58.
11. Johnston, N., Wells, C. W., Samuels, T. L. et al.: Pepsin in nonacidic refluxate can damage hypopharyngeal epithelial cells. The Annals of Otology, Rhinology & Laryngology, 118, 2009, s. 77-68.
12. Kiljander et al.: Effect of ezomeprazole 40 mg once or twice daily on asthma: A randomized, placebo-controlled. Am. J. Respir. Crit. Care Med., 181, 2010, s. 1042-1048.
13. Kim, Y. S., Kim, T. H., Choi, C. S. et al.: Effect of itopride, a new prokinetic, in patients with mild GERD: A pilot study. World J. Gastroenterol., 2005, 11, s. 4210-4214.
14. Koufman, J. A.: Laryngopharyngeal reflux is different from classic gastroesophageal reflux disease. Ear, Nose & Throat Journal, 81, 2002, s. 7-9.
15. Koufman. J. A.: The otolaryngologic manifestations of gastroesophageal reflux disease (GERD):a clinical investigation of 225 patients using ambulatory 24 hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope, 101, 1991, (Suppl. 53), s. 1-78.
16. Ludemann, J. P., Manoukkian, J., Shaw, K., Bernard, C., Al-Jubab, A.: Effects of simulated gastroesophageal reflux on the untraumatised rabbit larynx. J. Otolaryngol., 27, 1998, 3, s. 127-131.
17. Lukáš, K., Žák, A.: Léčba refluxní choroby jícnu – současný stav. Vnitř. Lék., 55, 2009, 10, s. 949-954.
18. Mamede, R. C. M., De Mello-Filho, F. V., Vigário, C. L. et al.: Effect of gastroesophageal reflux on hypertrophy of the base of the tongue. Otolaryngol. Head Neck Surg., 122, 2000, s. 607-610.
19. Orr, W. C.: Sleep-related gastro-oesophageal reflux as a distinct clinical entity. Aliment Pharm Therapeutics, 31, 2010, s. 47-56.
20. Payn, R. J., Kost, K. M., Frenkiel, S. et al.: Laryngeal inflammtion assessed using the reflux finding score in obstructive sleep apnea. Otolaryngol. Head Neck Surg., 134, 2006, s. 836-842.
21. Poelmans, J., Tack, J.: Extraoesophageal manifestations of gastro-oesophageal reflux. Gut, 54, 2005, 10, s. 1492-1499. doi: 10.1136/gut.2004.053025.
22. Refluxní choroba jícnu. Standardy České gastroenterologické společnosti - aktualizace 2009, http://www. cgs-cls.cz.
23. Samuels, T. L., Johnston, N.: Pepsin as a causal agent of inflamation during nonacidic reflux. Otolaryngol. Head Neck Surg., 141, 2009, s. 559-563.
24. Sataloff, R. T.: Gastroesophageal reflux-related chronic laryngitis. Arch. Otolaryngol. Head Neck Surg., 136, 2010, 9, s. 914-915.
25. Sataloff, R. T., Castell, D. O., Katz, P. O., Sataloff, D. M.: Reflux laryngitis and related disorders. Third edition. San Diego, California. Plural Publishing Inc., 2006, s. 52-53.
26. Strugala, V., Avis, J., Jolliffe, I. G. et al.: The role af an alginate suspension on pepsin and bile acids – key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? Journal of Pharmacy and Pharmacology, 61, 2009, s. 1021-1028.
27. Sečet, M. P., Patti, M. G., Hoopes, C., Hays, S. R., Golden, J. A.: Gastro-oesophageal reflux and aspiration in patients with advanced lung disease. Torax, 64, 2009, 2, s. 167-173.
28. Vseti, M. F.: Extraesophageal manifestations of gastroesophageal reflux disease. Clinical Cornerstone, 5, 2003, 4, s. 32-38.
29. Werner, G. J., Tsukashima, R., Kelly, C. et al.: Oropharyngeal pH monitoring for the detection of liquid and aerosolised supraesophageal gastric reflux. J. Voice, 23, 2009, s. 498-504.
30. Wise, S. K., Wise, J. C., DelGaudio, J. M.: Gastroesophageal reflux and laryngopharyngeal reflux in patients with sleep-disordered breathing. Otolaryngol. Head Neck Surg., 135, 2006, s. 253-257.
31. Zeleník, K., Komínek, P., Stárek, I. et al.: Extraezofageální reflux (1. část). Epidemiologie, patofyziologie a diagnostika., Otorinolaryng. a Foniat. /Prague/, 57, 2008, s. 143-150.
32. Zeleník, K., Kopřivová, H., Stárek, I., Schwarz, P., Komínek, P.: Reflux finding score. Otorinolaryng. a Foniat. /Prague/, 59, 2010, č. 1, s. 28-31.
Labels
Audiology Paediatric ENT ENT (Otorhinolaryngology)Article was published in
Otorhinolaryngology and Phoniatrics
2011 Issue 2
Most read in this issue
- Changes in Communication are the Biggest Handicap in Patients with Permanent Tracheostomy
- Extraesophageal Reflux Disease – Interdisciplinary Consensus
- Pendred Syndrome in the Czech Republic
-
Tumour Thrombosis of Internal Jugular Vein
A Case Report and Overview of Its Epidemiologic, Pathogenetic and Clinical Aspects